Mycoplasma pneumoniae: Walking Pneumonia, No Cell Wall, Diagnosis, Treatment

A school-age child has a mild cough, low-grade fever, and headache for over a week, but is still up and about, the classic picture of "walking pneumonia." The doctor prescribes amoxicillin. The child stays unwell, a chest x-ray shows patchy infiltrates, and paired serology shows rising Mycoplasma pneumoniae antibody.

The doctor switches to azithromycin, and within a couple of days the child improves. The amoxicillin did not make things worse; it did nothing at all. M. pneumoniae has no cell wall, and beta-lactam antibiotics work by attacking the cell wall, so there was no target for the drug to act on. That single fact, no cell wall, explains almost everything about this organism.

About Mycoplasma

Mycoplasma is the smallest free-living bacterium (about 0.2 to 0.8 micrometers), so small that it is below the reliable limit of the light microscope and can pass through filters that hold back most bacteria. It also has one of the smallest genomes of any free-living organism (roughly 500 to 1000 genes).

The single most important feature is that Mycoplasma has no cell wall. Almost every distinctive property follows from this one fact.

• No cell wall means no fixed shape, so M. pneumoniae is pleomorphic: round, pear-shaped, or filamentous.
• No cell wall means beta-lactam antibiotics (which target the cell wall) have nothing to act on, so M. pneumoniae is intrinsically resistant to all penicillins and cephalosporins. This is the point in the hook.
• No cell wall also means the organism does not Gram stain usefully and cannot be seen on a routine Gram film.
• Without the protection of a cell wall, M. pneumoniae is fragile and dries out easily, so it spreads person to person only through close contact by respiratory droplets. This is why outbreaks cluster in families, schools, and other close groups.

Most mycoplasmas are facultative anaerobes, but M. pneumoniae is a strict aerobe.

Figure: Spherical colonies of M. pneumoniae growing on SP4 agar(Source)

M. pneumoniae grows very slowly by binary fission, and its tiny colonies can take up to about three weeks to appear. On special media the colonies can show a "fried egg" shape (a denser center with a lighter edge), although M. pneumoniae colonies are often more granular and less classically "fried egg" than those of some other mycoplasmas.

Mycoplasmas are nutritionally demanding. Because they have no cell wall, they need sterols (such as cholesterol) to stabilize their membrane, so growth media must supply sterols. This sterol requirement is a defining feature of the group.

Extrapulmonary and autoimmune features

M. pneumoniae infection is well known for causing problems outside the lungs, through an autoimmune mechanism. The immune response against the organism can cross-react with the body's own cells.

• Cold agglutinins and hemolysis: many patients develop cold agglutinins, which are antibodies that clump red cells at low temperatures. In a minority of patients (around 10 percent may develop clinically significant hemolysis), these can cause cold-antibody hemolytic anemia. Cold agglutinins are a classic clue pointing to M. pneumoniae.
• Neurological disease: M. pneumoniae can trigger Guillain-Barré syndrome and other neurological complications, when antibodies against the organism cross-react with nerve tissue.
• Skin and mucous membranes: it can cause skin rashes and, in some cases, severe mucocutaneous disease (erythema multiforme and Stevens-Johnson-like reactions, sometimes called Mycoplasma-induced rash and mucositis).

These extrapulmonary features are exam favorites and are useful clinical clues, because they point to M. pneumoniae rather than an ordinary bacterial pneumonia.

As a separate practical point, mycoplasmas are a notorious contaminant of cell cultures in research and biotechnology laboratories. They are hard to detect and eliminate, which is why they are nicknamed the "crab grass" of cell culture.

Pathogenesis and Virulence

M. pneumoniae is an exclusively human pathogen, spread by respiratory droplets among close contacts. It causes a usually mild pneumonia, often called "walking pneumonia" because most patients are not sick enough to need hospital care. The pathogenesis has three parts.

Adhesion. M. pneumoniae has a specialized tip attachment organelle, with an adhesin protein called P1, that binds tightly to the respiratory epithelium. This close attachment lets the organism resist being swept away by the mucociliary clearance system, so it stays in the airway.

Direct injury and CARDS toxin. Once attached, it damages the ciliated epithelium and interferes with ciliary action. It also produces the Community-Acquired Respiratory Distress Syndrome (CARDS) toxin, which contributes to inflammation and airway dysfunction and is linked to more severe disease.

Immune-mediated damage. Much of the illness comes not from the organism destroying tissue directly, but from the host inflammatory and autoimmune response it provokes. This is the same cross-reacting immune response that produces the cold agglutinins and the extrapulmonary features above. It also helps explain why the x-ray can look worse than the patient (patchy infiltrates in a patient who is still walking around), a classic feature of atypical pneumonia.

Figure: Scanning electron micrograph of Mycoplasma pneumoniae cells

Laboratory Diagnosis

Diagnosing M. pneumoniae is not done by routine Gram stain or culture, and understanding why makes the whole approach clear.

Why not Gram stain? It has no cell wall, so it does not take the Gram stain and cannot be seen on a routine film.

Culture: possible but impractical. It is slow (up to about three weeks), needs special sterol-containing media, and is used only by some reference laboratories, not for everyday diagnosis.

Molecular testing (PCR): the primary method for laboratory identification, including in CDC guidance. Nucleic acid amplification (real-time PCR) is fast, sensitive, and specific, and works directly on respiratory samples. This is the modern first-line test.

Serology: detecting a rising antibody titer between paired acute and convalescent samples supports the diagnosis. Its main drawback is that a single early sample is often not enough, because the antibody rise takes time, so serology is more useful in retrospect than for immediate management.

Cold agglutinins: a positive cold-agglutinin test is a non-specific but classic bedside clue that supports M. pneumoniae when the clinical picture fits, though it is not diagnostic on its own.

Because it is a cause of atypical pneumonia, M. pneumoniae is compared with the other atypical-pneumonia organisms in the table on the Legionella pneumophila article.

Treatment of Mycoplasma pneumoniae infection

Treatment follows from the biology. Because M. pneumoniae has no cell wall, cell-wall-active antibiotics (all penicillins and cephalosporins) are useless. Effective drugs are those that act on other targets, mainly protein synthesis.

The first-line drugs are macrolides (such as azithromycin), which are usually preferred, especially in children. The alternatives, used when a macrolide cannot be used or is not working, are tetracyclines (such as doxycycline) and respiratory fluoroquinolones. Many M. pneumoniae infections are mild and self-limiting, so not every case needs antibiotics.

An important and current point: macrolide resistance in M. pneumoniae has become common, and it varies widely by region. Reported resistance is relatively low in some parts of the world (for example, low double digits in parts of the United States and Europe) but very high in parts of East Asia, where a large majority of strains can be resistant. Where macrolide resistance is common or when a patient is not responding to a macrolide, doxycycline or a fluoroquinolone is used instead. This regional difference is worth knowing, because it directly affects the right first choice of drug.

How to Remember

Key exam facts in one table

Where Students Get Confused

References

1. Tille, P. M. (2022). Bailey & Scott's Diagnostic Microbiology (15th ed.). Elsevier.
2. Procop, G. W., & Koneman, E. W. (2017). Koneman's Color Atlas and Textbook of Diagnostic Microbiology (7th ed.). Wolters Kluwer.
3. Carroll, K. C., Pfaller, M. A., et al. (2020). Murray's Medical Microbiology (9th ed.). Elsevier.
4. Centers for Disease Control and Prevention. Mycoplasma pneumoniae infections: clinical and laboratory guidance. CDC (current version).
5. Pereyre, S., Goret, J., & Bébéar, C. (2016). Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Frontiers in Microbiology, 7, 974.